Avior Wealth Management’s Immunovant IMVT Stock Holding History

Avior Wealth Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11	Closed	-$355	–	2967
2024 Q1	$355	Buy	+11	New	+$401	﹤0.01%	2674

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Avior Wealth Management's IMVT Position: Q2 2024 in Review

Avior Wealth Management sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 11 shares — an estimated $355 sold.

Avior Wealth Management first reported a position in IMVT in Q1 2024 and held it in 1 quarter. The position peaked at $355 in Q1 2024. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

Avior Wealth Management reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
Avior Wealth Management sold 11 Immunovant shares in Q2 2024, an estimated $355.
Avior Wealth Management first reported a position in Immunovant in Q1 2024 and held it in 1 quarter.
Avior Wealth Management's Immunovant position peaked at $355 in Q1 2024.
197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.